Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind weight-based fixed-dose paliperidone ER in adolescent schizophrenia
2007-000576-16Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paliperidone in schizophrenia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Primary efficacy, safety and tolerability.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2007-000576-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000576-16.